Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development of bone metastases and SREs in patients with EGFR+ NSCLC treate...
Saved in:
| Published in | JTO clinical and research reports Vol. 4; no. 5; p. 100513 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.05.2023
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2666-3643 2666-3643 |
| DOI | 10.1016/j.jtocrr.2023.100513 |
Cover
| Abstract | Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development of bone metastases and SREs in patients with EGFR+ NSCLC treated with osimertinib.
This is a retrospective multicenter cohort study that included patients with metastatic EGFR+ NSCLC who were treated with osimertinib between February 2016 and September 2021. Demographics, bone metastases-related outcomes, SREs, treatment efficacy, and overall survival (OS) were collected.
In total, 250 patients treated with osimertinib (43% first line) were included. Of the patients, 51% had bone metastases at initiation of osimertinib. Furthermore, 16% of the patients with bone metastases used bone-targeted agents. Median follow-up from initiation of osimertinib was 23.4 months (95% confidence interval [CI]: 19.9–26.9 mo). During osimertinib treatment, 10% developed new bone metastases or bone progression. Of the patients with bone metastases, 39% had more than or equal to one SREs: 28% developed first SRE before osimertinib treatment, 1% after, and 11% during. Median OS post-bone metastasis was 30.8 months (95% CI: 21.9–39.7). Median OS after first SRE was 31.1 months (95% CI: 15.8–46.5).
Bone metastases and SREs are frequent before and during treatment with osimertinib in EGFR+ NSCLC. Because of these findings and the long OS post-bone metastases, we advocate prescription of bone-targeted agents in these patients and recommend adding bone-specific end points in clinical trials. |
|---|---|
| AbstractList | AbstractIntroductionBone metastases are frequent in patients with EGFR-mutated ( EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development of bone metastases and SREs in patients with EGFR+ NSCLC treated with osimertinib. MethodsThis is a retrospective multicenter cohort study that included patients with metastatic EGFR+ NSCLC who were treated with osimertinib between February 2016 and September 2021. Demographics, bone metastases-related outcomes, SREs, treatment efficacy, and overall survival (OS) were collected. ResultsIn total, 250 patients treated with osimertinib (43% first line) were included. Of the patients, 51% had bone metastases at initiation of osimertinib. Furthermore, 16% of the patients with bone metastases used bone-targeted agents. Median follow-up from initiation of osimertinib was 23.4 months (95% confidence interval [CI]: 19.9–26.9 mo). During osimertinib treatment, 10% developed new bone metastases or bone progression. Of the patients with bone metastases, 39% had more than or equal to one SREs: 28% developed first SRE before osimertinib treatment, 1% after, and 11% during. Median OS post-bone metastasis was 30.8 months (95% CI: 21.9–39.7). Median OS after first SRE was 31.1 months (95% CI: 15.8–46.5). ConclusionsBone metastases and SREs are frequent before and during treatment with osimertinib in EGFR+ NSCLC. Because of these findings and the long OS post-bone metastases, we advocate prescription of bone-targeted agents in these patients and recommend adding bone-specific end points in clinical trials. Introduction: Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development of bone metastases and SREs in patients with EGFR+ NSCLC treated with osimertinib. Methods: This is a retrospective multicenter cohort study that included patients with metastatic EGFR+ NSCLC who were treated with osimertinib between February 2016 and September 2021. Demographics, bone metastases-related outcomes, SREs, treatment efficacy, and overall survival (OS) were collected. Results: In total, 250 patients treated with osimertinib (43% first line) were included. Of the patients, 51% had bone metastases at initiation of osimertinib. Furthermore, 16% of the patients with bone metastases used bone-targeted agents. Median follow-up from initiation of osimertinib was 23.4 months (95% confidence interval [CI]: 19.9–26.9 mo). During osimertinib treatment, 10% developed new bone metastases or bone progression. Of the patients with bone metastases, 39% had more than or equal to one SREs: 28% developed first SRE before osimertinib treatment, 1% after, and 11% during. Median OS post-bone metastasis was 30.8 months (95% CI: 21.9–39.7). Median OS after first SRE was 31.1 months (95% CI: 15.8–46.5). Conclusions: Bone metastases and SREs are frequent before and during treatment with osimertinib in EGFR+ NSCLC. Because of these findings and the long OS post-bone metastases, we advocate prescription of bone-targeted agents in these patients and recommend adding bone-specific end points in clinical trials. Bone metastases are frequent in patients with -mutated ( ) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development of bone metastases and SREs in patients with NSCLC treated with osimertinib. This is a retrospective multicenter cohort study that included patients with metastatic NSCLC who were treated with osimertinib between February 2016 and September 2021. Demographics, bone metastases-related outcomes, SREs, treatment efficacy, and overall survival (OS) were collected. In total, 250 patients treated with osimertinib (43% first line) were included. Of the patients, 51% had bone metastases at initiation of osimertinib. Furthermore, 16% of the patients with bone metastases used bone-targeted agents. Median follow-up from initiation of osimertinib was 23.4 months (95% confidence interval [CI]: 19.9-26.9 mo). During osimertinib treatment, 10% developed new bone metastases or bone progression. Of the patients with bone metastases, 39% had more than or equal to one SREs: 28% developed first SRE before osimertinib treatment, 1% after, and 11% during. Median OS post-bone metastasis was 30.8 months (95% CI: 21.9-39.7). Median OS after first SRE was 31.1 months (95% CI: 15.8-46.5). Bone metastases and SREs are frequent before and during treatment with osimertinib in NSCLC. Because of these findings and the long OS post-bone metastases, we advocate prescription of bone-targeted agents in these patients and recommend adding bone-specific end points in clinical trials. Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development of bone metastases and SREs in patients with EGFR+ NSCLC treated with osimertinib.IntroductionBone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development of bone metastases and SREs in patients with EGFR+ NSCLC treated with osimertinib.This is a retrospective multicenter cohort study that included patients with metastatic EGFR+ NSCLC who were treated with osimertinib between February 2016 and September 2021. Demographics, bone metastases-related outcomes, SREs, treatment efficacy, and overall survival (OS) were collected.MethodsThis is a retrospective multicenter cohort study that included patients with metastatic EGFR+ NSCLC who were treated with osimertinib between February 2016 and September 2021. Demographics, bone metastases-related outcomes, SREs, treatment efficacy, and overall survival (OS) were collected.In total, 250 patients treated with osimertinib (43% first line) were included. Of the patients, 51% had bone metastases at initiation of osimertinib. Furthermore, 16% of the patients with bone metastases used bone-targeted agents. Median follow-up from initiation of osimertinib was 23.4 months (95% confidence interval [CI]: 19.9-26.9 mo). During osimertinib treatment, 10% developed new bone metastases or bone progression. Of the patients with bone metastases, 39% had more than or equal to one SREs: 28% developed first SRE before osimertinib treatment, 1% after, and 11% during. Median OS post-bone metastasis was 30.8 months (95% CI: 21.9-39.7). Median OS after first SRE was 31.1 months (95% CI: 15.8-46.5).ResultsIn total, 250 patients treated with osimertinib (43% first line) were included. Of the patients, 51% had bone metastases at initiation of osimertinib. Furthermore, 16% of the patients with bone metastases used bone-targeted agents. Median follow-up from initiation of osimertinib was 23.4 months (95% confidence interval [CI]: 19.9-26.9 mo). During osimertinib treatment, 10% developed new bone metastases or bone progression. Of the patients with bone metastases, 39% had more than or equal to one SREs: 28% developed first SRE before osimertinib treatment, 1% after, and 11% during. Median OS post-bone metastasis was 30.8 months (95% CI: 21.9-39.7). Median OS after first SRE was 31.1 months (95% CI: 15.8-46.5).Bone metastases and SREs are frequent before and during treatment with osimertinib in EGFR+ NSCLC. Because of these findings and the long OS post-bone metastases, we advocate prescription of bone-targeted agents in these patients and recommend adding bone-specific end points in clinical trials.ConclusionsBone metastases and SREs are frequent before and during treatment with osimertinib in EGFR+ NSCLC. Because of these findings and the long OS post-bone metastases, we advocate prescription of bone-targeted agents in these patients and recommend adding bone-specific end points in clinical trials. Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development of bone metastases and SREs in patients with EGFR+ NSCLC treated with osimertinib. This is a retrospective multicenter cohort study that included patients with metastatic EGFR+ NSCLC who were treated with osimertinib between February 2016 and September 2021. Demographics, bone metastases-related outcomes, SREs, treatment efficacy, and overall survival (OS) were collected. In total, 250 patients treated with osimertinib (43% first line) were included. Of the patients, 51% had bone metastases at initiation of osimertinib. Furthermore, 16% of the patients with bone metastases used bone-targeted agents. Median follow-up from initiation of osimertinib was 23.4 months (95% confidence interval [CI]: 19.9–26.9 mo). During osimertinib treatment, 10% developed new bone metastases or bone progression. Of the patients with bone metastases, 39% had more than or equal to one SREs: 28% developed first SRE before osimertinib treatment, 1% after, and 11% during. Median OS post-bone metastasis was 30.8 months (95% CI: 21.9–39.7). Median OS after first SRE was 31.1 months (95% CI: 15.8–46.5). Bone metastases and SREs are frequent before and during treatment with osimertinib in EGFR+ NSCLC. Because of these findings and the long OS post-bone metastases, we advocate prescription of bone-targeted agents in these patients and recommend adding bone-specific end points in clinical trials. |
| ArticleNumber | 100513 |
| Author | Steendam, Christi Dingemans, Anne-Marie C. van Veelen, Ard Hendriks, Lizza E.L. van der Leest, Cor Veerman, G. D. Marijn Dursun, Safiye Croes, Sander Brouns, Anita J.W. M. |
| Author_xml | – sequence: 1 givenname: Anita J.W. M. orcidid: 0000-0003-3701-2729 surname: Brouns fullname: Brouns, Anita J.W. M. organization: Department of Respiratory Medicine, Zuyderland, The Netherlands – sequence: 2 givenname: Ard surname: van Veelen fullname: van Veelen, Ard organization: Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands – sequence: 3 givenname: G. D. Marijn surname: Veerman fullname: Veerman, G. D. Marijn organization: Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands – sequence: 4 givenname: Christi surname: Steendam fullname: Steendam, Christi organization: Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands – sequence: 5 givenname: Safiye surname: Dursun fullname: Dursun, Safiye organization: Department of Respiratory Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands – sequence: 6 givenname: Cor surname: van der Leest fullname: van der Leest, Cor organization: Department of Respiratory Medicine, Amphia Hospital Breda, Breda, The Netherlands – sequence: 7 givenname: Sander surname: Croes fullname: Croes, Sander organization: Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands – sequence: 8 givenname: Anne-Marie C. surname: Dingemans fullname: Dingemans, Anne-Marie C. organization: Department of Respiratory Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands – sequence: 9 givenname: Lizza E.L. orcidid: 0000-0002-3521-2535 surname: Hendriks fullname: Hendriks, Lizza E.L. email: lizza.hendriks@mumc.nl organization: Department of Respiratory Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37168878$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVUl1r1EAUDVKxtfYfiOTRl6wzmWQyK6Losq0LWyvdio_DfNy0k2aTOpMs9N97k7TSClKEQCZ37jkn957zMtpr2gai6DUlM0oof1fNqq413s9SkjIskZyyZ9FByjlPGM_Y3oPzfnQUQkUISXNKC5G-iPZZQbkQhTiI-lVjnIXGQNyW8RdUiU-hUwEfCLFqbLy5hhordXIOterAxssdNF2IXRN_V50bzz9ddxUvT47Pk9O-G5u-bRbrRXzhYfwa78-C24LvXOP0q-h5qeoAR3fvw-jH8fJi8TVZn52sFp_XieFMdIniVBChCq0KJRixIsUpaK5JDqTUFOxciEzrPNMGStyL5iq3cygos8qaUrHDaDXx2lZV8sa7rfK3slVOjoXWX0qFf2RqkHNEUq7EvNA843OtM6RFNWN1YTVo5Po0cd30egvW4OBe1Y9IH9807kpetjs5GIb2ZMjw9o7Bt796CJ3cumCgrlUDbR9kKijLcyEYw9Y3D8X-qNwbhw3vpwbj2xA8lNI43LxrB21Xo-ioKys5BUUOQZFTUBCc_QW-538C9nGCAVq2c-BlMG6IjnUeTIc7df9LYGqMg1H1NdxCqNreNxgHSWVIJZGbIcJDglOGvufpMPWHfxM8rf8bjHQDIQ |
| CitedBy_id | crossref_primary_10_1111_crj_70043 crossref_primary_10_1007_s00586_024_08447_8 crossref_primary_10_31083_j_fbl2905184 crossref_primary_10_3389_fonc_2025_1438120 crossref_primary_10_7759_cureus_66240 |
| Cites_doi | 10.3390/cancers13133144 10.2478/raon-2014-0038 10.1016/j.annonc.2020.07.019 10.1016/S1470-2045(11)70393-X 10.1634/theoncologist.2019-0285 10.1016/j.ejca.2011.05.008 10.1200/JCO.19.01154 10.1200/JCO.2003.04.105 10.2217/fon-2018-0613 10.1186/s12885-022-09245-5 10.1016/j.jtho.2015.10.001 10.1007/s00520-013-2094-y 10.3389/fonc.2016.00208 10.1097/JTO.0b013e318206a1e3 10.1007/s00520-013-1951-z 10.1080/15384047.2016.1195049 10.1016/S1470-2045(16)30508-3 10.1002/cncr.27409 10.1001/jamaoncol.2015.4921 10.21037/cco.2016.11.02 10.1634/theoncologist.9-90004-14 10.2217/fon-2021-0356 10.18632/oncotarget.14427 10.3389/fonc.2020.588862 10.1007/s00520-013-2022-1 10.2217/fon-2016-0163 10.18632/oncotarget.5515 10.1016/j.jtho.2020.06.011 10.1093/annonc/mdi122 10.1016/j.lungcan.2020.08.017 10.1056/NEJMoa1713137 10.1016/j.lungcan.2014.01.006 10.1056/NEJMoa1612674 10.1016/j.canlet.2008.12.019 10.1016/j.lungcan.2018.05.006 10.1093/annonc/mdy275 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors The Authors 2023 The Authors. 2023 The Authors 2023 |
| Copyright_xml | – notice: 2023 The Authors – notice: The Authors – notice: 2023 The Authors. – notice: 2023 The Authors 2023 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.jtocrr.2023.100513 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2666-3643 |
| EndPage | 100513 |
| ExternalDocumentID | oai_doaj_org_article_95d916a897b6469bb454b001cdb7dbeb PMC10165134 37168878 10_1016_j_jtocrr_2023_100513 S2666364323000528 1_s2_0_S2666364323000528 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Takeda – fundername: Bayer funderid: https://doi.org/10.13039/100004326 – fundername: Roche Genentech – fundername: Lilly – fundername: AstraZeneca funderid: https://doi.org/10.13039/100004325 – fundername: Pfizer funderid: https://doi.org/10.13039/100004319 – fundername: Boehringer Ingelheim – fundername: Merck funderid: https://doi.org/10.13039/100004334 – fundername: Amgen funderid: https://doi.org/10.13039/100002429 – fundername: Eli Lilly funderid: https://doi.org/10.13039/100004312 |
| GroupedDBID | .1- .FO 0R~ 1P~ 53G AAEDW AALRI AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL RPM Z5R AAHOK AFCTW NCXOZ 0SF 6I. AAFTH AAYXX CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c638t-a61808a7ba7a830d8200015b05e0fb1ed9884bb54bcef101b6a5d9e713dadcfa3 |
| IEDL.DBID | DOA |
| ISSN | 2666-3643 |
| IngestDate | Wed Aug 27 01:34:58 EDT 2025 Thu Aug 21 18:37:12 EDT 2025 Thu Sep 04 21:12:36 EDT 2025 Wed Feb 19 02:23:43 EST 2025 Thu Apr 24 22:53:49 EDT 2025 Tue Jul 01 03:31:44 EDT 2025 Tue Oct 01 06:57:07 EDT 2024 Tue Feb 25 19:54:55 EST 2025 Tue Aug 26 19:33:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Bone targeted agents Lung adenocarcinoma Solid tumors Bone metastases related outcomes Tyrosine kinase inhibitor |
| Language | English |
| License | This is an open access article under the CC BY license. 2023 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c638t-a61808a7ba7a830d8200015b05e0fb1ed9884bb54bcef101b6a5d9e713dadcfa3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-3521-2535 0000-0003-3701-2729 |
| OpenAccessLink | https://doaj.org/article/95d916a897b6469bb454b001cdb7dbeb |
| PMID | 37168878 |
| PQID | 2813558833 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_95d916a897b6469bb454b001cdb7dbeb pubmedcentral_primary_oai_pubmedcentral_nih_gov_10165134 proquest_miscellaneous_2813558833 pubmed_primary_37168878 crossref_citationtrail_10_1016_j_jtocrr_2023_100513 crossref_primary_10_1016_j_jtocrr_2023_100513 elsevier_sciencedirect_doi_10_1016_j_jtocrr_2023_100513 elsevier_clinicalkeyesjournals_1_s2_0_S2666364323000528 elsevier_clinicalkey_doi_10_1016_j_jtocrr_2023_100513 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-01 |
| PublicationDateYYYYMMDD | 2023-05-01 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JTO clinical and research reports |
| PublicationTitleAlternate | JTO Clin Res Rep |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Lorenzi, Ferro, Cecere (bib23) Soria, Ohe, Vansteenkiste (bib12) 2018; 378 Henry, Vadhan-Raj, Hirsh (bib16) 2014; 22 von Moos, Body, Rider (bib17) 2018; 11 Hagiwara, Delea, Cong, Chung (bib20) 2014; 22 Zwitter, Rajer, Stanic (bib26) 2016; 17 Atagi, Goto, Seto (bib27) 2016; 12 Berghmans, Lievens, Aapro (bib47) 2020; 150 Planchard, Popat, Kerr (bib43) 2018; 29 Coleman, Hadji, Body (bib13) 2020; 31 O’Carrigan, Wong, Willson, Stockler, Pavlakis, Goodwin (bib14) 2017; 10 Jacobson, Cadieux, Higano (bib39) 2022; 34 Doebele, Lu, Sumey (bib8) 2012; 118 Zwitter, Stanic, Rajer (bib24) 2014; 48 Coleman (bib6) 2004; 9 Daniele, Sandro, Salvatore (bib5) 2015; 5 Mok, Wu, Ahn (bib30) 2017; 376 Goss, Tsai, Shepherd (bib29) 2016; 17 Hirano, Naka, Takeda (bib28) 2016; 5 Brouns, Dursun, Bootsma, Dingemans, Hendriks (bib11) 2021; 13 Kuijpers, Hendriks, Derks (bib7) 2018; 121 Cui, Li, Gu (bib45) 2019; 18 Zhang, Cheng, Zhang (bib36) 2017; 7 Hendriks, Hermans, van den Beuken-van Everdingen, Hochstenbag, Dingemans (bib18) 2016; 11 Weinfurt, Li, Castel (bib38) 2005; 16 Calderone, Nimako, Leary, Popat, O’Brien (bib19) 2011; 47 Oster, Lamerato, Glass (bib21) 2014; 22 bib48 Peters, Danson, Hasan (bib2) 2020; 15 Noronha, Patil, Joshi (bib32) 2020; 38 Bahce, Claessens, Comans (bib40) Zheng, Wang, Xu (bib31) 2019; 24 bib41 Rosell, Carcereny, Gervais (bib10) 2012; 13 Ahmed, Muzaffar, Fernandes, Tu, Albalooshi, Osman (bib34) 2016; 6 bib42 Huang, Wang, Feng (bib46) 2016; 7 Decroisette, Monnet, Berard (bib22) 2011; 6 Kunikane, Yokota, Katakami (bib37) 2019; 17 Chang, Hsieh, Shen (bib44) 2009; 278 Silva, Silva, Bergmann, Thuler (bib3) 2019; 15 Russo, Franchina, Ricciardi (bib9) 2017; 8 Rosen, Gordon, Tchekmedyian (bib15) 2003; 21 Zeng, Guo, Zhou (bib33) 2022; 22 Dal Maso, Lorenzi, Ferro (bib35) 2021; 17 Hendriks, Smit, Vosse (bib1) 2014; 84 Lagana, Gurizzan, Roca (bib4) 2020; 10 Park, Yu, Kim (bib25) 2016; 2 Coleman (10.1016/j.jtocrr.2023.100513_bib13) 2020; 31 Kunikane (10.1016/j.jtocrr.2023.100513_bib37) 2019; 17 Lagana (10.1016/j.jtocrr.2023.100513_bib4) 2020; 10 Dal Maso (10.1016/j.jtocrr.2023.100513_bib35) 2021; 17 Zwitter (10.1016/j.jtocrr.2023.100513_bib24) 2014; 48 Hendriks (10.1016/j.jtocrr.2023.100513_bib18) 2016; 11 von Moos (10.1016/j.jtocrr.2023.100513_bib17) 2018; 11 Chang (10.1016/j.jtocrr.2023.100513_bib44) 2009; 278 Hirano (10.1016/j.jtocrr.2023.100513_bib28) 2016; 5 Daniele (10.1016/j.jtocrr.2023.100513_bib5) 2015; 5 Jacobson (10.1016/j.jtocrr.2023.100513_bib39) 2022; 34 Henry (10.1016/j.jtocrr.2023.100513_bib16) 2014; 22 Zwitter (10.1016/j.jtocrr.2023.100513_bib26) 2016; 17 Planchard (10.1016/j.jtocrr.2023.100513_bib43) 2018; 29 Kuijpers (10.1016/j.jtocrr.2023.100513_bib7) 2018; 121 Atagi (10.1016/j.jtocrr.2023.100513_bib27) 2016; 12 Hendriks (10.1016/j.jtocrr.2023.100513_bib1) 2014; 84 Calderone (10.1016/j.jtocrr.2023.100513_bib19) 2011; 47 Lorenzi (10.1016/j.jtocrr.2023.100513_bib23) Park (10.1016/j.jtocrr.2023.100513_bib25) 2016; 2 Rosen (10.1016/j.jtocrr.2023.100513_bib15) 2003; 21 Huang (10.1016/j.jtocrr.2023.100513_bib46) 2016; 7 Bahce (10.1016/j.jtocrr.2023.100513_bib40) Doebele (10.1016/j.jtocrr.2023.100513_bib8) 2012; 118 Berghmans (10.1016/j.jtocrr.2023.100513_bib47) 2020; 150 Zhang (10.1016/j.jtocrr.2023.100513_bib36) 2017; 7 Silva (10.1016/j.jtocrr.2023.100513_bib3) 2019; 15 Ahmed (10.1016/j.jtocrr.2023.100513_bib34) 2016; 6 O’Carrigan (10.1016/j.jtocrr.2023.100513_bib14) 2017; 10 Mok (10.1016/j.jtocrr.2023.100513_bib30) 2017; 376 Russo (10.1016/j.jtocrr.2023.100513_bib9) 2017; 8 Weinfurt (10.1016/j.jtocrr.2023.100513_bib38) 2005; 16 Coleman (10.1016/j.jtocrr.2023.100513_bib6) 2004; 9 Noronha (10.1016/j.jtocrr.2023.100513_bib32) 2020; 38 Rosell (10.1016/j.jtocrr.2023.100513_bib10) 2012; 13 Oster (10.1016/j.jtocrr.2023.100513_bib21) 2014; 22 Zheng (10.1016/j.jtocrr.2023.100513_bib31) 2019; 24 Brouns (10.1016/j.jtocrr.2023.100513_bib11) 2021; 13 Hagiwara (10.1016/j.jtocrr.2023.100513_bib20) 2014; 22 Decroisette (10.1016/j.jtocrr.2023.100513_bib22) 2011; 6 Peters (10.1016/j.jtocrr.2023.100513_bib2) 2020; 15 Soria (10.1016/j.jtocrr.2023.100513_bib12) 2018; 378 Goss (10.1016/j.jtocrr.2023.100513_bib29) 2016; 17 Zeng (10.1016/j.jtocrr.2023.100513_bib33) 2022; 22 Cui (10.1016/j.jtocrr.2023.100513_bib45) 2019; 18 |
| References_xml | – volume: 378 start-page: 113 year: 2018 end-page: 125 ident: bib12 article-title: Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer publication-title: N Engl J Med – volume: 22 start-page: 1363 year: 2014 end-page: 1373 ident: bib21 article-title: Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems publication-title: Support Care Cancer – volume: 47 start-page: 1603 year: 2011 end-page: 1605 ident: bib19 article-title: Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease—a short communication publication-title: Eur J Cancer – volume: 34 year: 2022 ident: bib39 article-title: Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: a real-world machine learning approach publication-title: J Bone Oncol – volume: 22 start-page: 103 year: 2014 end-page: 113 ident: bib20 article-title: Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer publication-title: Support Care Cancer – volume: 12 start-page: 2117 year: 2016 end-page: 2126 ident: bib27 article-title: Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two phase II studies publication-title: Future Oncol – volume: 11 start-page: 1 year: 2018 end-page: 9 ident: bib17 article-title: Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries publication-title: J Bone Oncol – volume: 21 start-page: 3150 year: 2003 end-page: 3157 ident: bib15 article-title: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the zoledronic acid Lung Cancer and Other Solid Tumors Study Group publication-title: J Clin Oncol – volume: 22 start-page: 198 year: 2022 ident: bib33 article-title: Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters publication-title: BMC Cancer – volume: 376 start-page: 629 year: 2017 end-page: 640 ident: bib30 article-title: Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer publication-title: N Engl J Med – volume: 10 start-page: CD003474 year: 2017 ident: bib14 article-title: Bisphosphonates and other bone agents for breast cancer publication-title: Cochrane Database Syst Rev – volume: 17 start-page: 1320 year: 2019 end-page: 1326 ident: bib37 article-title: Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13) publication-title: Oncol Lett – ident: bib23 article-title: First-line osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: outcome and safety in the real world: FLOWER study [e-pub ahead of print]. – volume: 38 start-page: 124 year: 2020 end-page: 136 ident: bib32 article-title: Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer publication-title: J Clin Oncol – volume: 17 start-page: 833 year: 2016 end-page: 839 ident: bib26 article-title: Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations publication-title: Cancer Biol Ther – volume: 15 start-page: 485 year: 2019 end-page: 494 ident: bib3 article-title: Bone metastases and skeletal-related events: incidence and prognosis according to histological subtype of lung cancer publication-title: Future Oncol – ident: bib41 article-title: Botmetastasen – volume: 18 start-page: 5437 year: 2019 end-page: 5447 ident: bib45 article-title: Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor-treated patients with non-small cell lung cancer exhibiting bone metastasis publication-title: Oncol Lett – volume: 118 start-page: 4502 year: 2012 end-page: 4511 ident: bib8 article-title: Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer publication-title: Cancer – ident: bib42 article-title: Non-Small Cell Lung Cancer. NCCN Guidelines, version 3.2023 – volume: 7 start-page: 66480 year: 2016 end-page: 66490 ident: bib46 article-title: Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: a retrospective study publication-title: Oncotarget – ident: bib40 article-title: Guideline: niet-kleincelling longcarcinoom – volume: 13 start-page: 3144 year: 2021 ident: bib11 article-title: Reporting of incidence and outcome of bone metastases in clinical trials enrolling patients with epidermal growth factor receptor mutated lung adenocarcinoma—a systematic review publication-title: Cancers (Basel) – volume: 24 year: 2019 ident: bib31 article-title: Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations publication-title: Oncologist – volume: 17 start-page: 2513 year: 2021 end-page: 2527 ident: bib35 article-title: Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines publication-title: Future Oncol – volume: 13 start-page: 239 year: 2012 end-page: 246 ident: bib10 article-title: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial publication-title: Lancet Oncol – volume: 22 start-page: 679 year: 2014 end-page: 687 ident: bib16 article-title: Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors publication-title: Support Care Cancer – volume: 150 start-page: 221 year: 2020 end-page: 239 ident: bib47 article-title: European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): lung cancer publication-title: Lung Cancer – volume: 11 start-page: 155 year: 2016 end-page: 173 ident: bib18 article-title: Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: a systematic review publication-title: J Thorac Oncol – volume: 278 start-page: 17 year: 2009 end-page: 26 ident: bib44 article-title: Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells publication-title: Cancer Lett – volume: 10 year: 2020 ident: bib4 article-title: High prevalence and early occurrence of skeletal complications in EGFR mutated NSCLC patients with bone metastases publication-title: Front Oncol – volume: 17 start-page: 1643 year: 2016 end-page: 1652 ident: bib29 article-title: Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study publication-title: Lancet Oncol – volume: 9 start-page: 14 year: 2004 end-page: 27 ident: bib6 article-title: Bisphosphonates: clinical experience publication-title: Oncologist – volume: 121 start-page: 76 year: 2018 end-page: 81 ident: bib7 article-title: Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer publication-title: Lung Cancer – volume: 5 year: 2015 ident: bib5 article-title: Natural history of non-small-cell lung cancer with bone metastases publication-title: Sci Rep – volume: 48 start-page: 361 year: 2014 end-page: 368 ident: bib24 article-title: Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations publication-title: Rad Oncol – volume: 16 start-page: 579 year: 2005 end-page: 584 ident: bib38 article-title: The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer publication-title: Ann Oncol – volume: 29 start-page: iv192 year: 2018 end-page: iv237 ident: bib43 article-title: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 8 start-page: 8717 year: 2017 end-page: 8725 ident: bib9 article-title: Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer publication-title: Oncotarget – volume: 31 start-page: 1650 year: 2020 end-page: 1663 ident: bib13 article-title: Bone health in cancer: ESMO Clinical Practice Guidelines publication-title: Ann Oncol – volume: 6 start-page: 576 year: 2011 end-page: 582 ident: bib22 article-title: Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601) publication-title: J Thorac Oncol – volume: 5 start-page: 77 year: 2016 ident: bib28 article-title: A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation publication-title: Chin Clin Oncol – volume: 15 start-page: 1647 year: 2020 end-page: 1656 ident: bib2 article-title: A randomized open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: the European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR trial publication-title: J Thorac Oncol – volume: 6 start-page: 208 year: 2016 ident: bib34 article-title: Skeletal metastasis as detected by 18F-FDG PET with negative CT of the PET/CT: frequency and impact on cancer staging and/or management publication-title: Front Oncol – ident: bib48 article-title: 6th LuCE Report on Lung Cancer: Experiences and Quality of Life of People Impacted by Lung Cancer in Europe – volume: 7 year: 2017 ident: bib36 article-title: Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases publication-title: Sci Rep – volume: 2 start-page: 305 year: 2016 end-page: 312 ident: bib25 article-title: First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study publication-title: JAMA Oncol – volume: 84 start-page: 86 year: 2014 end-page: 91 ident: bib1 article-title: EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases? publication-title: Lung Cancer – volume: 13 start-page: 3144 year: 2021 ident: 10.1016/j.jtocrr.2023.100513_bib11 article-title: Reporting of incidence and outcome of bone metastases in clinical trials enrolling patients with epidermal growth factor receptor mutated lung adenocarcinoma—a systematic review publication-title: Cancers (Basel) doi: 10.3390/cancers13133144 – volume: 48 start-page: 361 year: 2014 ident: 10.1016/j.jtocrr.2023.100513_bib24 article-title: Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations publication-title: Rad Oncol doi: 10.2478/raon-2014-0038 – volume: 31 start-page: 1650 year: 2020 ident: 10.1016/j.jtocrr.2023.100513_bib13 article-title: Bone health in cancer: ESMO Clinical Practice Guidelines publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.07.019 – volume: 13 start-page: 239 year: 2012 ident: 10.1016/j.jtocrr.2023.100513_bib10 article-title: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70393-X – volume: 24 year: 2019 ident: 10.1016/j.jtocrr.2023.100513_bib31 article-title: Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations publication-title: Oncologist doi: 10.1634/theoncologist.2019-0285 – volume: 47 start-page: 1603 year: 2011 ident: 10.1016/j.jtocrr.2023.100513_bib19 article-title: Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease—a short communication publication-title: Eur J Cancer doi: 10.1016/j.ejca.2011.05.008 – volume: 38 start-page: 124 year: 2020 ident: 10.1016/j.jtocrr.2023.100513_bib32 article-title: Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.19.01154 – volume: 21 start-page: 3150 year: 2003 ident: 10.1016/j.jtocrr.2023.100513_bib15 article-title: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the zoledronic acid Lung Cancer and Other Solid Tumors Study Group publication-title: J Clin Oncol doi: 10.1200/JCO.2003.04.105 – ident: 10.1016/j.jtocrr.2023.100513_bib40 – volume: 7 year: 2017 ident: 10.1016/j.jtocrr.2023.100513_bib36 article-title: Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases publication-title: Sci Rep – volume: 15 start-page: 485 year: 2019 ident: 10.1016/j.jtocrr.2023.100513_bib3 article-title: Bone metastases and skeletal-related events: incidence and prognosis according to histological subtype of lung cancer publication-title: Future Oncol doi: 10.2217/fon-2018-0613 – volume: 22 start-page: 198 year: 2022 ident: 10.1016/j.jtocrr.2023.100513_bib33 article-title: Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters publication-title: BMC Cancer doi: 10.1186/s12885-022-09245-5 – volume: 11 start-page: 155 year: 2016 ident: 10.1016/j.jtocrr.2023.100513_bib18 article-title: Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: a systematic review publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2015.10.001 – volume: 22 start-page: 1363 year: 2014 ident: 10.1016/j.jtocrr.2023.100513_bib21 article-title: Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems publication-title: Support Care Cancer doi: 10.1007/s00520-013-2094-y – volume: 10 start-page: CD003474 year: 2017 ident: 10.1016/j.jtocrr.2023.100513_bib14 article-title: Bisphosphonates and other bone agents for breast cancer publication-title: Cochrane Database Syst Rev – volume: 6 start-page: 208 year: 2016 ident: 10.1016/j.jtocrr.2023.100513_bib34 article-title: Skeletal metastasis as detected by 18F-FDG PET with negative CT of the PET/CT: frequency and impact on cancer staging and/or management publication-title: Front Oncol doi: 10.3389/fonc.2016.00208 – volume: 6 start-page: 576 year: 2011 ident: 10.1016/j.jtocrr.2023.100513_bib22 article-title: Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601) publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e318206a1e3 – volume: 22 start-page: 103 year: 2014 ident: 10.1016/j.jtocrr.2023.100513_bib20 article-title: Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer publication-title: Support Care Cancer doi: 10.1007/s00520-013-1951-z – volume: 17 start-page: 833 year: 2016 ident: 10.1016/j.jtocrr.2023.100513_bib26 article-title: Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations publication-title: Cancer Biol Ther doi: 10.1080/15384047.2016.1195049 – volume: 17 start-page: 1643 year: 2016 ident: 10.1016/j.jtocrr.2023.100513_bib29 article-title: Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30508-3 – volume: 118 start-page: 4502 year: 2012 ident: 10.1016/j.jtocrr.2023.100513_bib8 article-title: Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer publication-title: Cancer doi: 10.1002/cncr.27409 – ident: 10.1016/j.jtocrr.2023.100513_bib23 – volume: 2 start-page: 305 year: 2016 ident: 10.1016/j.jtocrr.2023.100513_bib25 article-title: First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.4921 – volume: 5 start-page: 77 year: 2016 ident: 10.1016/j.jtocrr.2023.100513_bib28 article-title: A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation publication-title: Chin Clin Oncol doi: 10.21037/cco.2016.11.02 – volume: 17 start-page: 1320 year: 2019 ident: 10.1016/j.jtocrr.2023.100513_bib37 article-title: Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13) publication-title: Oncol Lett – volume: 9 start-page: 14 issue: suppl 4 year: 2004 ident: 10.1016/j.jtocrr.2023.100513_bib6 article-title: Bisphosphonates: clinical experience publication-title: Oncologist doi: 10.1634/theoncologist.9-90004-14 – volume: 17 start-page: 2513 year: 2021 ident: 10.1016/j.jtocrr.2023.100513_bib35 article-title: Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines publication-title: Future Oncol doi: 10.2217/fon-2021-0356 – volume: 8 start-page: 8717 year: 2017 ident: 10.1016/j.jtocrr.2023.100513_bib9 article-title: Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer publication-title: Oncotarget doi: 10.18632/oncotarget.14427 – volume: 11 start-page: 1 year: 2018 ident: 10.1016/j.jtocrr.2023.100513_bib17 article-title: Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries publication-title: J Bone Oncol – volume: 10 year: 2020 ident: 10.1016/j.jtocrr.2023.100513_bib4 article-title: High prevalence and early occurrence of skeletal complications in EGFR mutated NSCLC patients with bone metastases publication-title: Front Oncol doi: 10.3389/fonc.2020.588862 – volume: 22 start-page: 679 year: 2014 ident: 10.1016/j.jtocrr.2023.100513_bib16 article-title: Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors publication-title: Support Care Cancer doi: 10.1007/s00520-013-2022-1 – volume: 18 start-page: 5437 year: 2019 ident: 10.1016/j.jtocrr.2023.100513_bib45 article-title: Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor-treated patients with non-small cell lung cancer exhibiting bone metastasis publication-title: Oncol Lett – volume: 12 start-page: 2117 year: 2016 ident: 10.1016/j.jtocrr.2023.100513_bib27 article-title: Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two phase II studies publication-title: Future Oncol doi: 10.2217/fon-2016-0163 – volume: 7 start-page: 66480 year: 2016 ident: 10.1016/j.jtocrr.2023.100513_bib46 article-title: Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: a retrospective study publication-title: Oncotarget doi: 10.18632/oncotarget.5515 – volume: 15 start-page: 1647 year: 2020 ident: 10.1016/j.jtocrr.2023.100513_bib2 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2020.06.011 – volume: 34 year: 2022 ident: 10.1016/j.jtocrr.2023.100513_bib39 article-title: Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: a real-world machine learning approach publication-title: J Bone Oncol – volume: 16 start-page: 579 year: 2005 ident: 10.1016/j.jtocrr.2023.100513_bib38 article-title: The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdi122 – volume: 150 start-page: 221 year: 2020 ident: 10.1016/j.jtocrr.2023.100513_bib47 article-title: European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2020.08.017 – volume: 378 start-page: 113 year: 2018 ident: 10.1016/j.jtocrr.2023.100513_bib12 article-title: Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1713137 – volume: 84 start-page: 86 year: 2014 ident: 10.1016/j.jtocrr.2023.100513_bib1 article-title: EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases? publication-title: Lung Cancer doi: 10.1016/j.lungcan.2014.01.006 – volume: 376 start-page: 629 year: 2017 ident: 10.1016/j.jtocrr.2023.100513_bib30 article-title: Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1612674 – volume: 278 start-page: 17 year: 2009 ident: 10.1016/j.jtocrr.2023.100513_bib44 article-title: Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells publication-title: Cancer Lett doi: 10.1016/j.canlet.2008.12.019 – volume: 5 year: 2015 ident: 10.1016/j.jtocrr.2023.100513_bib5 article-title: Natural history of non-small-cell lung cancer with bone metastases publication-title: Sci Rep – volume: 121 start-page: 76 year: 2018 ident: 10.1016/j.jtocrr.2023.100513_bib7 article-title: Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2018.05.006 – volume: 29 start-page: iv192 issue: suppl 4 year: 2018 ident: 10.1016/j.jtocrr.2023.100513_bib43 article-title: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdy275 |
| SSID | ssj0002511782 |
| Score | 2.269652 |
| Snippet | Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE... AbstractIntroductionBone metastases are frequent in patients with EGFR-mutated ( EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients;... Bone metastases are frequent in patients with -mutated ( ) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in... Introduction: Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however,... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 100513 |
| SubjectTerms | Bone metastases related outcomes Bone targeted agents Hematology, Oncology, and Palliative Medicine Lung adenocarcinoma Original Solid tumors Tyrosine kinase inhibitor |
| Title | Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666364323000528 https://www.clinicalkey.es/playcontent/1-s2.0-S2666364323000528 https://dx.doi.org/10.1016/j.jtocrr.2023.100513 https://www.ncbi.nlm.nih.gov/pubmed/37168878 https://www.proquest.com/docview/2813558833 https://pubmed.ncbi.nlm.nih.gov/PMC10165134 https://doaj.org/article/95d916a897b6469bb454b001cdb7dbeb |
| Volume | 4 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4s3yqIzE1cKJ48Q50tUuFWILYlvRm2XHjpoWsqjJ_n9m7GS1AaTlwDGJHcszk_m-ccZjQt567hIArpxV0uUsq2TBSmsdS6VwBhBJOYtLA6uz_PQi-3gpL_eO-sKcsFgeOAruXSkdMBijysLmEMpZm8kMkb5ytnDWW_S-vOR7wRT6YCTORTgpCgAoZwJwd9w3F5K7rvtNdYvlQFOBeQIyERNcCuX7J_D0J_38PYtyD5aWD8j9gU_S93EeD8kd3z4id1fDH_PHZAsOIJ4bSjc1Pdm0nq58b4ATdr6jpnV0fQPIAxSchbw47-gCUyA72rT0Syy62tFvTX9FFx-WX9lq24dGZ-v5pzk9R8oJV-H55675gVnabWOfkIvl4nx-yoajFlgFH2DPTJ4orkxhTWGU4E6lYZO15dLz2ibelUpl1oLoK1-DDG1uQC8eIlxnXFUb8ZQctTCF54Sa2grhaulTB1TLc5urGkiYg1dJIwszI2IUtK6GOuR4HMZ3PSacXeuoHo3q0VE9M8J2vX7GOhwH2p-gDndtsYp2uAG2pQfb0odsa0bkaAF63KgKrhVe1BwYvPhbP98N_qHTie5SzfUarRONEwJBXKBX-z0HChSpzT-M-WY0UQ0eAn_7mNZvtp1OVYI19JWANs-iye7EIiBcBpiBcdXEmCdymz5pm6tQhTxshEtE9uJ_SPoluYdziZmkr8hRf7v1r4Ht9fY4fNjHYRnuF8iDUvw |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incidence+of+Bone+Metastases+and+Skeletal-Related+Events+in+Patients+With+EGFR-Mutated+NSCLC+Treated+With+Osimertinib&rft.jtitle=JTO+clinical+and+research+reports&rft.au=Brouns%2C+Anita+J.W.+M.&rft.au=van+Veelen%2C+Ard&rft.au=Veerman%2C+G.+D.+Marijn&rft.au=Steendam%2C+Christi&rft.date=2023-05-01&rft.pub=Elsevier+Inc&rft.issn=2666-3643&rft.eissn=2666-3643&rft.volume=4&rft.issue=5&rft_id=info:doi/10.1016%2Fj.jtocrr.2023.100513&rft.externalDocID=S2666364323000528 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2666-3643&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2666-3643&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2666-3643&client=summon |